
Jan 11 (Reuters) - Zymeworks Inc ZYME.O:
ZYMEWORKS OUTLINES STRATEGIC PRIORITIES AND OUTLOOK FOR 2026
ZYMEWORKS: UP TO $440 MILLION IN MILESTONE PAYMENTS ELIGIBLE TO BE EARNED RELATED TO REGULATORY APPROVALS OF ZIIHERA IN GEA IN UNITED STATES, EUROPE, JAPAN, & CHINA
ZYMEWORKS INC: GLOBAL PHASE 1 CLINICAL TRIAL INVESTIGATING ZW191 IN SOLID TUMORS IS ONGOING WITH DOSE OPTIMIZATION OF ZW191 IN OVARIAN CANCER